Lawrence N. Barrera

BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB

Stuart A. Rushworth, Kristian M. Bowles, Lawrence N. Barrera et al. · Cellular Signalling · 2012 · 106 citations

Medicine, Oncology, Pharmacology +12

<scp>UHRF1</scp> regulation of the Keap1–Nrf2 pathway in pancreatic cancer contributes to oncogenesis

Wafa AbuAlainin, Thompson Gana, Triantafillos Liloglou et al. · The Journal of Pathology · 2015 · 58 citations · Full text

Medicine, Molecular Biology, Oncology +15

Insulin, leptin, and adiponectin receptors in colon: regulation relative to differing body adiposity independent of diet and in response to dimethylhydrazine

Janice E. Drew, Andrew J. Farquharson, Sara Padidar et al. · American Journal of Physiology-Gastrointestinal and Liver Physiology · 2007 · 45 citations

Life Sciences, Cancer Biology, Endocrinology +14

Bortezomib induces heme oxygenase-1 expression in multiple myeloma

Lawrence N. Barrera, Stuart A. Rushworth, Kristian M. Bowles et al. · Cell Cycle · 2012 · 44 citations · Full text

Medicine, Oncology, Pharmacology +16

Custom Design of a GeXP Multiplexed Assay Used to Assess Expression Profiles of Inflammatory Gene Targets in Normal Colon, Polyp, and Tumor Tissue

Janice E. Drew, Claus Mayer, Andrew J. Farquharson et al. · Journal of Molecular Diagnostics · 2011 · 33 citations · Full text

Medicine, Cancer Biology, Molecular Medicine +17